International Boehringer Ingelheim Research & Development Press Conference

Our Research & Development Drive

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

Awards & Fellowships

Boehringer Ingelheim's Research & Development facts:
  • Our research & development comprises four major research & development sites and three support centres worldwide.
  • During the past decade, Boehringer Ingelheim conducted or sponsored 1,223 studies with 125 substances in 58 countries from all regions of the world.
  • We have more than 6,700 highly qualified people working in research & development out of 41,300 Boehringer Ingelheim employees worldwide.
  • Our drug discovery focuses on seven major therapeutic areas: Cardiovascular Diseases, Central Nervous System Diseases (CNS), Immunology & Inflammation, Metabolic Diseases, Oncology, Respiratory Diseases, Virology.
  • In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending more than 22% of net sales in its largest business segment Prescription Medicines on research and development.

back to top